Protein Geranylgeranyltransferase Type I Subunit Beta

Protein Geranylgeranyltransferase Type I Subunit Beta (PGGT1B) is a crucial enzyme involved in the post-translational modification of proteins, specifically in the process known as prenylation. This enzyme, along with its counterpart subunit alpha, forms the heterodimeric protein geranylgeranyltransferase type I (GGTase-I), which plays a vital role in the modification of various protein substrates by attaching a geranylgeranyl group to their carboxyl-terminal cysteine residues. This modification is essential for the proper localization and function of these proteins within the cell.

Function

PGGT1B is responsible for the geranylgeranylation of proteins, a type of lipid modification that is critical for the proper functioning of several intracellular signaling pathways. This modification affects proteins that contain a C-terminal CAAX motif (where C is cysteine, A is an aliphatic amino acid, and X is any amino acid). The geranylgeranyl group, a 20-carbon isoprenoid, is covalently attached to the cysteine residue, facilitating the protein's attachment to cell membranes and influencing its interaction with other cellular components.

Structure

The structure of PGGT1B, as part of the GGTase-I complex, is characterized by its ability to recognize and bind to the CAAX motif of target proteins. The enzyme is composed of two subunits: the beta subunit (PGGT1B), which is primarily involved in substrate recognition, and the alpha subunit, which is implicated in the catalytic activity of the enzyme. The precise structure of PGGT1B and its interaction with the alpha subunit and substrates is crucial for the enzyme's specificity and function.

Clinical Significance

Alterations in the activity or expression of PGGT1B can have significant implications for human health. Dysregulation of protein prenylation has been linked to various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. In cancer, for example, the overexpression of proteins that require geranylgeranylation for their oncogenic activity has been observed. Consequently, inhibitors of PGGT1B and the GGTase-I complex are being explored as potential therapeutic agents for the treatment of these conditions.

Research and Therapeutic Applications

The study of PGGT1B and its inhibitors has opened new avenues for the development of targeted therapies. By inhibiting the function of PGGT1B, it is possible to disrupt the prenylation of oncogenic proteins, thereby hindering their ability to promote tumor growth and metastasis. Several small molecule inhibitors of GGTase-I are currently under investigation in preclinical and clinical trials for their potential use in cancer therapy.

See Also

• Prenylation
• Protein prenyltransferases
• Geranylgeranyltransferase
• Cancer therapy

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian